Literature DB >> 3276281

An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.

J R Davidson1, E L Giller, S Zisook, J E Overall.   

Abstract

Isocarboxazid and placebo were evaluated in 130 anxious depressives. Drug was superior to placebo on depression, anxiety, interpersonal sensitivity, and global measures, and on symptoms of hostility, anxiety, obsessiveness, and psychological-cognitive components of depression. There were no significant differences between treatment effects on psychomotor and typical vegetative symptoms. Isocarboxazid was more effective than placebo in major, but not in minor, depression. It was significantly more effective in depression classified as endogenous depression or melancholia by various diagnostic criteria. Drug was more effective than placebo in atypical depression with vegetative reversal and in Brief Psychiatric Rating Scale (BPRS)-derived profiles of anxious and hostile depression; there were no drug-placebo differences in atypical depression without vegetative reversal, or in BPRS retarded and agitated/excited depression. Interpersonal sensitivity emerged as an important drug-responsive dimension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276281     DOI: 10.1001/archpsyc.1988.01800260024003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  7 in total

1.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

2.  Predictors of response to monoamine oxidase inhibitors: do they exist?

Authors:  J R Davidson; E L Giller; S Zisook; M J Helms
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

3.  Testing atypical depression definitions.

Authors:  Franco Benazzi
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

Review 4.  Atypical depression: a comprehensive review.

Authors:  Chi-Un Pae; Haresh Tharwani; David M Marks; Prakash S Masand; Ashwin A Patkar
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 5.  Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.

Authors:  Y Lecrubier
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

Review 6.  Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis.

Authors:  Corrado Barbui; Andrea Cipriani; Vikram Patel; José L Ayuso-Mateos; Mark van Ommeren
Journal:  Br J Psychiatry       Date:  2011-01       Impact factor: 9.319

7.  Major Depressive Disorder and Kappa Opioid Receptor Antagonists.

Authors:  Wei Li; Huijiao Sun; Hao Chen; Xicheng Yang; Li Xiao; Renyu Liu; Liming Shao; Zhuibai Qiu
Journal:  Transl Perioper Pain Med       Date:  2016
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.